Is Hims / Ro Legit for Weight Loss? Telehealth GLP-1 Review 2026

Searching "is Hims legit" or "is Ro legit" for weight loss brings you to the same crossroad: two giant telehealth brands promising GLP-1 access without a traditional doctor visit, but with very different fine print. Hims & Hers (Hims Weight Loss) and Ro (Ro Body) both offer prescription weight-loss treatment online — yet one leans heavily on compounded semaglutide made by compounding pharmacies, and the other has pivoted to FDA-approved-only brand-name drugs at retail prices.

Our answer, based on corporate records, pricing pages, FDA and Department of Justice actions, and thousands of verified reviews (Trustpilot, BBB): Both Hims and Ro are legitimate, licensed telehealth platforms — not scams — but they carry real regulatory, cost, and subscription risks that buyers must understand before paying $39 today and $149/month tomorrow.

This is the RatingFacts Editorial Team's August 2026 verification of Hims / Ro Weight Loss. We scored them the same way we score every business on our platform: company verification, payment/subscription transparency, regulatory history, scam-safety indicators, and the actual experience of buyers.

What Hims and Ro Actually Sell for Weight Loss

Both platforms run a membership + medication model: you pay a monthly membership for access to prescribers, coaching/messaging, and — in Ro's case — insurance help; you pay separately for the medication itself, either via insurance or cash-pay.

Ro Body (Roman Health Ventures, Inc.) — Founded 2017, New York City

Originally "Roman" (men's sexual health), Ro expanded to weight loss (Ro Body), dermatology, fertility, and primary care. In 2026 its lineup is FDA-approved-only:

• Wegovy pill (semaglutide) — $149 first month, $199–$299 ongoing. Prepay & Save can cut ~$50/mo on annual prepay.
• Found (orforglipron) — Lilly's new oral GLP-1 (approved 2025). Same $149 → $199–$299 bracket, matching LillyDirect cash price.
• Zepbound KwikPen (tirzepatide) — injectable, $299 first month, $399–$449 ongoing (LillyDirect parity).
• Wegovy pen (semaglutide) — $199 first month, $199–$399 ongoing, with up to $150/mo savings on highest dose via annual prepay.
• Ozempic — insurance only ($900–$1,100 without insurance; no cash-pay via Ro).

Ro's compounded semaglutide line that drove growth in 2024 is gone as of June 2026. Membership: $39 first month (promotional), then $149/month month-to-month or as low as $74/month if you prepay 12 months. Membership covers provider visits, Quest labs (in 44 states; at-home kit in NY/NJ/RI/ND/SD/WY), insurance concierge, unlimited messaging, weight/dose tracking, and 1:1 coaching. You are only charged after approval. Labs at Quest are included. Insurance-pickup meds go to your local pharmacy within ~2 weeks; cash-pay ships directly.

Cancellation: cancel anytime before next cycle; past fees are not refundable (including the $39), no prorated refund mid-cycle.

Hims & Hers Health (Hims Weight Loss) — Publicly Traded (NYSE: HIMS)

Hims offers both brand-name and compounded options under one roof (Ozempic, Wegovy, Zepbound + compounded semaglutide and generic liraglutide), via a large provider network and a polished app. Members repeatedly praise fast onboarding and 24/7 messaging.

• Membership: advertised $39 first month, then ongoing monthly. Lowest advertised rates often require multi-month upfront payment.
• Does Hims accept insurance? No — weight-loss program is cash-pay only for compounded meds; brand-name via insurance is limited. HSA/FSA cards are accepted.
• Refills: auto-renew; multiple reviewers report refills processing earlier than expected, sometimes weeks before stated date, and no refunds once shipped (medication can't be returned).
• Cancellation: must cancel 48 hours before next order date; exceptions are case-by-case.

Hims also offers access in most states (not all 50 explicitly guaranteed), no in-house labs, and no dietitian access in the review snapshot — scope is prescription-centric.

Are Hims and Ro Legit Companies?

Yes — both are real, licensed US telehealth companies:

• Ro is operated by Roman Health Ventures, Inc., NYC, founded 2017. Delivers care in all 50 states.
• Hims & Hers is a US public company with an A+ BBB rating (important trust signal), wide prescriber network, and partnerships with FDA-registered compounding pharmacies. Its app, onboarding, and messaging are consistently rated strong for access and cost transparency (GLP-1 Reviews scores Hims 4.7/5 Access, 4.6/5 Cost & Value).

"Legit" does not mean "risk-free." The companies' regulatory histories diverge sharply — and that history matters for weight-loss buyers in 2026.

The Regulatory Record: Why Hims Carries More Risk in 2026

Timeline matters because compounded GLP-1 rules changed quickly:

• May 2024: Hims begins prescribing compounded GLP-1s for weight loss.
• Jan 2025: Hims airs a Super Bowl ad promoting affordable weight loss. Novo Nordisk answers with national print ads questioning compounded-GLP-1 safety.
• Feb 2025: FDA declares the semaglutide injectable shortage resolved, which complicates the legal basis for compounding semaglutide at scale.
• Apr 2025: Novo Nordisk and Hims announce a partnership to offer branded Wegovy through Hims — a surprise truce.
• Jun 2025: Novo terminates the partnership after ~8 weeks, accusing Hims of continuing compounded sales alongside Wegovy and "deceptive marketing." Hims stock fell ~22% premarket.
• Sep 9, 2025: FDA issues a warning letter to Hims & Hers objecting to marketing that positioned compounded semaglutide as equivalent to FDA-approved products.
• Feb 2026: Novo Nordisk files a federal patent-infringement lawsuit seeking to block Hims from selling compounded semaglutide; the FDA separately refers Hims to the Department of Justice. (Reuters, Feb 2026)
• Mar 2026: FDA warns 30 telehealth firms over misleading compounded-GLP-1 marketing; filings note Hims among the ecosystem under scrutiny.

What this means for you: compounded semaglutide from Hims is prepared by compounding pharmacies — legal under 503A/503B frameworks when shortage or patient-specific need applies, but not FDA-approved as a finished drug product. Quality, potency, and labeling vary more than brand-name drugs. After the shortage resolution and the FDA warning + DOJ referral, the runway for mass-market compounded semaglutide is narrowing; legal and supply risk is higher than in 2024. Ro's pivot to FDA-approved-only sidesteps this risk entirely — but at full brand-price pain.

What Real Customers Say

Trustpilot / BBB Snapshot (June–March 2026)

What Patients Like

• Provider access: both platforms get frequent praise for real provider messaging, often within hours. Ro's insurance concierge gets specific callouts — members report $25–$50 copays where they expected $1,000+.
• App/ops: Hims' app (messaging, tracking, refills) and Ro's all-in-one hub (chat, labs, dose tracking, coaching) reduce friction.
• Retention as signal: Hims reports 75% still on treatment at 6 months — a retention pattern consistent with GLP-1 efficacy when tolerated.

What Patients Don't Like

• The $39 trap: the #1 complaint trigger for Ro is mistaking the $39 first-month promotional membership for the ongoing rate; the next charge is $149. Ro's FAQ states it clearly, but entry marketing does not always.
• Cancellation friction: both platforms draw complaints about charges after cancellation attempts and difficulty confirming cancellation or getting a refund on the entry fee if not approved.
• Early refills / shipped-order refunds: Hims reviews frequently cite early auto-refills and no refunds once shipped — understandable for medication, painful when timing is unexpected.
• Compounded-drug anxiety: post-shortage, buyers increasingly ask whether their compounded vial matches the labeled potency — compounding is not held to the same lot-release testing as branded lots.

Costs Compared: The Real Monthly Total

Bottom line: both platforms are expensive once you include membership. Brand-name GLP-1s deliver proven weight-loss efficacy (≈15–20% body weight on tirzepatide at 72 weeks in trials; 1–2 lb/week at therapeutic doses), but you pay brand pricing. Compounded alternatives lower sticker price today but add legal/quality uncertainty after Feb 2026 actions.

Pros and Cons

RatingFacts Verdict: Legit, Not Scams — Pick by Your Priority

Neither Hims nor Ro is a scam. Both are licensed telehealth operators with real prescribers, real pharmacies, and real prescriptions. Reviews confirm real deliveries and real weight-loss outcomes when patients tolerate GLP-1s and stay adherent.

But which is the better value in August 2026 depends on what you value most:

• Choose Ro if you want the lowest regulatory risk (brand-name only), you have insurance that might cover a GLP-1 (Ro's concierge may turn $1,000 into $25–$50), and you want labs + coaching bundled — and you can tolerate $74–$149/mo on top of the med.
• Choose Hims if you want a simple, fast, app-first experience and don't mind cash-pay compounded GLP-1s with the trade-offs above. Put it on a credit card, understand the auto-refill cadence, and document cancellation.
• Consider a third path if you want bundled labs + dietitian access beyond prescription, or you want non-GLP-1 options (metformin / bupropion-naltrexone) alongside GLP-1s — shops like Found or Noom Med market those bundles, with their own cost/complexity.

Our advice regardless:

1. Verify total price (membership + med + labs) before the $39 period ends.
2. Pay with a credit card for dispute rights; confirm your cancellation window in writing.
3. Talk to your primary care provider about risks/benefits, especially if you have a history of pancreatitis, gallbladder disease, or thyroid C-cell issues — labels for GLP-1s carry specific contraindications.
4. Check Hims reviews and Ro reviews on RatingFacts, plus Trustpilot and BBB, before you decide — and revisit after the next regulatory filing.

Frequently Asked Questions

Is Hims legit for weight loss?

Yes — Hims is a legitimate publicly traded telehealth company with licensed prescribers and an A+ BBB rating. Its weight-loss program is cash-pay and offers both brand-name and compounded GLP-1s. The main risks are subscription/refill friction and legal uncertainty around compounded semaglutide after the FDA warning and Novo lawsuit.

Is Ro legit for weight loss?

Yes — Ro (Ro Body) is a legitimate telehealth company (Roman Health Ventures, NYC, since 2017) delivering care in all 50 states. In 2026 its lineup is FDA-approved-only, with labs included and an insurance concierge. The main complaints relate to the $39 first-month price being mistaken for the ongoing rate and to shipping/cancellation friction.

How much does Ro Body cost?

Ro Body is $39 for the first month, then $149/month month-to-month or as low as $74/month prepaid annually, plus medication. Cash-pay examples: Wegovy or Found pill $149 first month then $199–$299 ongoing; Zepbound KwikPen $299 first month then $399–$449.

Does Hims still offer compounded semaglutide?

As of March–June 2026 reporting, Hims still listed compounded semaglutide alongside brand-name options, but it is operating under an FDA warning letter, a DOJ referral, and a Novo Nordisk patent lawsuit — all targeting compounded-GLP-1 marketing and sales. Expect the compounded runway to be constrained.

Does Ro still sell compounded semaglutide?

No. Ro's June 2026 page confirms its current weight-loss lineup is FDA-approved-only; the compounded semaglutide line is discontinued.

Which is cheaper overall — Hims or Ro?

Cash-pay totals are similar once you include membership. Ro can be cheaper net if your insurance covers a GLP-1 and the concierge gets you a low copay; Hims can be cheaper on sticker alone if you choose a low-cost compounded plan and prepay months. Always compare membership + medication, not medication alone.

Is compounded semaglutide safe?

Compounding is legal when done by licensed pharmacies under FDA rules, but compounded drugs are not FDA-approved finished products and do not go through the same lot-release testing as branded lots. That creates more variability. Discuss formulation-specific risks with your prescriber and consider whether FDA-approved brand-name options fit your budget and goals.

Methodology & Sources

This review was produced by the RatingFacts Editorial Team (author: Sarah Mitchell, Senior Reviews Editor). Prose synthesizes primary disclosures (company pricing pages, FDA, court filings), structured review-platform sampling (Trustpilot, BBB, RatingFacts), and industry reporting. 2026-specific claims are dated and sourced. Pricing verified on Hims.com and Ro.co June–August 2026; regulatory timeline from FDA warning letter (Sep 9, 2025), Reuters (Feb 2026 lawsuit + DOJ referral; June 2025 partnership termination), and AP/Reuters coverage of the Feb 2025 semaglutide shortage resolution. Rating snapshots as of March–June 2026. This is informational, not medical advice — consult a licensed healthcare professional for eligibility.

• Dosemate — Ro Weight Loss Reviews 2026: Cost, GLP-1s, Is It Legit? (June 8, 2026)
• HealthFacts Journal — Hims Weight Loss Review 2026
• WeightLossProviderGuide — Hims GLP-1 Reviews (Mar 4, 2026) — Timeline & 75% 6-mo retention
• FormBlends — Hims Weight Loss Review 2026: GLP-1 Program Breakdown
• GLP-1 Reviews — Hims/Hers 4.0/5 Scorecard (April 10, 2026)
• FDA — Warning Letter: Hims & Hers Health, Inc. (Sep 9, 2025)
• Reuters — Novo Nordisk patent suit & DOJ referral (Feb 2026); partnership end (June 2025)
• RatingFacts — Hims reviews & Ro reviews